Back to search results

Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care

Abroad (travel likely)Recruiting

Conditions

Fractures, Bone · Nonunion of Fracture · Fractures, Open · Fractures, Ununited · Fracture, Tibial · Fracture of Femur · Fracture Arm

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • OrlandoHealth, Orlando, Florida, United States

    Contact: Study coordinator (David Krol) · david.krol@orlandohealth.com
    Contact: Principal Investigator (M. Kareem Shaath, MD)

  • RWJBarnabas Health, Jersey City, New Jersey, United States

    Contact: Study coordinator (Ian Hong, MD candidate) · ian.hong@rwjbh.org · 914 671 7325
    Contact: Principal Investigator (Richard Yoon, MD)

  • Duke University Medical Center, Durham, North Carolina, United States

    Contact: Study coordinator (Carrigan Creech, BS) · carrigan.creech@duke.edu
    Contact: Principal Investigator (Malcolm DeBaun, MD)

  • Sentara Hospitals, Norfolk, Virginia, United States

    Contact: Study coordinator (Susan Steele, RN, CCRC) · srsteel1@Sentara.com · 757 803 3280
    Contact: Principal Investigator (Richard Myers, MD)
Study leads

  • Alyce Jones, Ph.D

    Study Director

    LifeNet Health

View source on ClinicalTrials.gov(opens in a new tab)